Subsequently, we further quantified CD57+CD8+ T cells in tumor tissues using the mIHC/IF method, suggesting that the frequency trend of CD57+CD8+ T cells in tumor tissues was consistent with that in peripheral blood, which could be used to predict the anti-PD-1 response. This evidence concerns the gene CD8A and neoplasm.